Adocia (XPAR:ADOC) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ADOC Adocia XPAR:ADOC
32 GF Score
Price €3.84
GF Value €0.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:ADOC
32GF Score
Adocia XPAR:ADOC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (XPAR:ADOC) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.84 is trading 331.5% above its estimated GF Value™ of €0.89. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for XPAR:ADOC:

  • Short Ratio:
  • GF Value™: €0.89 vs. price of €3.84 (331.5% above fair value)
  • GF Score™: 32/100 with 7 warning signs

No single metric tells the full story. See the XPAR:ADOC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges 0QAI:UKA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
32GF Score

Get the complete analysis for XPAR:ADOC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.84
Price
€0.89
GF Value